R21/Matrix-M Malaria Vaccine Leveraging Novavax’s Adjuvant Technology Gains Additional Authorization
The authorizations are based on Phase 2b trial results published in The Lancet Infectious Diseases, as well as…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Jul 23
The authorizations are based on Phase 2b trial results published in The Lancet Infectious Diseases, as well as…
25 Jul 23
First registered, randomized Phase 3 trial in hidradenitis suppurativa (HS) evaluating the efficacy and safety of upadacitinib (RINVOQ)…
25 Jul 23
altona has recently launched the FlexStar® CT & NG PCR Detection Mix 1.5 (RUO), our first product of the…
24 Jul 23
Ycanth is a drug-device combination that contains a formulation of cantharidin (0.7%w/v) delivered through a single-use applicator, for…
24 Jul 23
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations…
24 Jul 23
The Phase 3 ENHANCE trial is a randomised, double-blind study that was intended to assess the combination of…
24 Jul 23
The Albanese Government has today launched the first major update to the cardiovascular disease prevention guidelines in over…
24 Jul 23
Clinical labs face critical operational challenges that impede productivity—more patient samples to test, staffing shortages, and more documentation…
24 Jul 23
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products,…
24 Jul 23
The company intends to further extend its global reach, which has been focused on Southeast Asia and Latin…